DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for neoplasm — screening already-approved drugs against its 49-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeoplasm maps to a 49-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BCR activator of RhoGEF and GTPase (BCR) — BCR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ip2drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5OC7 · 1.652 Å · ligand D-MYO-INOSITOL-4,5-BISPHOSPHATE (IP2). Experimental structure, not a prediction.
What the evidence adds up to
In a 2018 analysis of 45 patients with myeloid/lymphoid neoplasms carrying FGFR1 rearrangement, the 1-year overall survival from diagnosis was 43.1%. Among those with myeloproliferative neoplasm or myelodysplastic syndromes, the cumulative incidence of transformation to blast phase at 12 months was 46.2%. Allogeneic haematopoietic stem cell transplantation was performed in 13 patients, with a 1-year survival of 61.5% after transplant; the hazard ratio for mortality with transplant as a time-dependent covariate was 0.34 (95% CI 0.08–1.51, P = 0.15), suggesting a possible benefit but not reaching statistical significance. Achieving complete response by 2 months after diagnosis of blast phase was associated with better 1-year survival from that point (40.0% vs 26.0%, P = 0.011).
A 2025 Italian multicentre retrospective study examined interleukin inhibitors (IL-23, IL-17, IL-12/23) in 136 patients with plaque psoriasis and a history of neoplasm. Of these, 116 had developed the neoplasm before starting the biologic, with a mean interval of 8.31 years from cancer diagnosis to first biologic dose. Twenty patients received a diagnosis of neoplasm during treatment with IL inhibitors, after a mean of 2.41 years on the biologic, yielding a cumulative incidence of 3.06 per 1000 individuals. Three patients had neoplasm recurrence while on IL inhibitors, leading to drug discontinuation. The authors state that biologics appeared safe and effective in this population but call for larger, longer studies.
A 2021 case report describes low-grade fibromyxoid sarcoma as an infrequent neoplasm, occurring in approximately 0.7% of all cases, with late aggressive metastatic behaviour. The report notes that perineal hernias are unusual, with fewer than 100 cases in the world literature, and that the presentation of this sarcoma as the content of a primary perineal hernia is even rarer.
What remains missing across these studies are prospective, controlled trials with sufficient sample sizes to establish standard therapy for FGFR1-rearranged neoplasms, longer follow-up and larger cohorts to confirm the safety of interleukin inhibitors in patients with active or prior cancer, and any systematic data on treatment outcomes for low-grade fibromyxoid sarcoma beyond single case reports. No drug repurposing data are present in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Hematology · 2018 · 37 citations · open access
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (<i>FGFR1</i>) rearrangement
AbstractOBJECTIVE: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy. METHODS: We experienced a patient with T-lymphoblastic lymphoma (LBL) associated with FGFR1 rearrangement who underwent cord blood transplantation, but died of pulmonary complication. We collected the clinical data of patients with FGFR1 rearrangement from the medical literature and analyzed 45 patients, including our patient. RESULTS: The primary diagnoses were myeloproliferative neoplasm (MPN) or myelodysplastic syndromes (MDS) in 14 and acute leukemia or LBL in 31. In MPN and MDS patients, the cumulative incidence of transformation to blast phase (BP) at 12 months was 46.2%. The 1-year overall survival (OS) from diagnosis in all cases was 43.1%. With regard to the impact of treatment response on survival, the achievement of complete response with a landmark at 2 months after diagnosis of BP was associated with a superior OS (40.0% vs. 26.0% P = 0.011 for 1-year OS from BP). Allogeneic hematopoietic stem cell transplantation (HSCT) was performed in 13 patients, and the 1-year OS from allogeneic HSCT was 61.5%. The hazard ratio for mortality was 0.34 (95% CI, 0.08-1.51, P = 0.15) for allogeneic HSCT treated as a time-dependent covariate, which suggests that allogeneic HSCT may confer a clinical benefit. CONCLUSION: The further accumulation of clinical data is needed to determine the optimal therapeutic approach for these neoplasms.
Journal of Dermatological Treatment · 2025 · 4 citations · open access
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
AbstractInterleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals. Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies.
Cirugía y Cirujanos · 2021 · 0 citations · open access
Sarcoma fibromixoide de bajo grado como contenido de hernia perineal. Reporte de un caso
AbstractANTECEDENTES: El sarcoma fibromixoide de bajo grado es una neoplasia rara de histología someramente benigna, pero con un comportamiento agresivo metastásico tardío. Las hernias perineales son de presentación inusitada y no existen más de 100 casos reportados en la literatura mundial. DISCUSIÓN: La presentación de esta neoplasia fibroblástica es poco frecuente, y aún más como contenido de una hernia perineal primaria. CONCLUSIÓN: Es una neoplasia infrecuente que se presenta en aproximadamente el 0.7% de los casos, con comportamiento agresivo metastásico y con necesidad de tratamiento adyuvante. BACKGROUND: Low-grade fibromyxoid sarcoma is a rare neoplasm with apparently benign histology but with late aggressive metastatic behavior. The perineal hernias are unusual, there are no more than 100 cases reported in the world literature. DISCUSSION: The presentation of this fibroblastic neoplasm is rare and makes it even more rare if it is as the content of a primary perineal hernia. CONCLUSION: It is an infrequent neoplasm that occurs in approximately 0.7% of all cases, with aggressive metastatic behavior and in need of adjuvant treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
